🇺🇸 FDA
Patent

US 10064889

Mercapto-modified biocompatible macromolecule derivatives with low degree of mercapto-modification and the cross-linked materials and uses thereof

granted A61KA61K31/573A61K31/728

Quick answer

US patent 10064889 (Mercapto-modified biocompatible macromolecule derivatives with low degree of mercapto-modification and the cross-linked materials and uses thereof) held by BIOREGEN BIOMEDICAL (CHANGZHOU) CO., LTD. expires Mon Aug 30 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BIOREGEN BIOMEDICAL (CHANGZHOU) CO., LTD.
Grant date
Tue Sep 04 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 30 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/573, A61K31/728, A61K31/737, A61K31/738